Widely used:Recently Viewed
Clear All
Today’s Range
52 Week Range
Liquidity
Market cap
$1,293 Mln
P/E Ratio
--
P/B Ratio
22.4
Industry P/E
--
Debt to Equity
6.8
ROE
-2.47 %
ROCE
-60.31 %
Div. Yield
0 %
Book Value
0.75
EPS
-4.07
CFO
$-647.62 Mln
EBITDA
$-1,038.47 Mln
Net Profit
$-1,089.84 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Travere Therapeutics (TVTX)
| -14.35 | -24.38 | -19.22 | 142.60 | -20.45 | 2.08 | -4.78 |
|
BSE Sensex
| 0.39 | 6.40 | 1.96 | 7.69 | 10.43 | 20.75 | 10.61 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|---|
|
Travere Therapeutics (TVTX)
| 92.73 | -57.25 | -32.25 | 13.89 | 91.94 | -37.25 | 7.36 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 | 9.57 | 20.86 | -9.70 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 36.19 | 10,117.70 | 20.54 | 23.13 | |
| 296.28 | 8,962.72 | 23.48 | 58.42 | |
| 24.72 | 9,739.03 | -- | -28.77 | |
| 101.38 | 9,903.71 | 30.43 | 14.16 |
Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases in the United States. The company's products include FILSPARI (sparsentan), a once-daily,... oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. Its clinical-stage programs consist of Sparsentan, a novel investigational product candidate, which has been granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerosis in the U.S. and Europe; and Pegtibatinase (TVT-058), a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria. It has a collaboration agreement with PharmaKrysto Limited for the pre-clinical activities associated with the cystinuria program. The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California. Address: 3611 Valley Centre Drive, San Diego, CA, United States, 92130 Read more
President, CEO & Director
Dr. Eric M. Dube Ph.D.
President, CEO & Director
Dr. Eric M. Dube Ph.D.
Headquarters
San Diego, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Travere Therapeutics Inc (TVTX) stood at $ 594 Mln as on 31-Dec-24
The share price of Travere Therapeutics Inc (TVTX) is $14.92 (NASDAQ) as of 17-Apr-2025 16:00 EDT. Travere Therapeutics Inc (TVTX) has given a return of -20.45% in the last 3 years.
Travere Therapeutics Inc (TVTX) has a market capitalisation of $ 1,293 Mln as on 17-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of Travere Therapeutics Inc (TVTX) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Travere Therapeutics Inc (TVTX) and enter the required number of quantities and click on buy to purchase the shares of Travere Therapeutics Inc (TVTX).
Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases in the United States. The company's products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. Its clinical-stage programs consist of Sparsentan, a novel investigational product candidate, which has been granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerosis in the U.S. and Europe; and Pegtibatinase (TVT-058), a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria. It has a collaboration agreement with PharmaKrysto Limited for the pre-clinical activities associated with the cystinuria program. The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California. Address: 3611 Valley Centre Drive, San Diego, CA, United States, 92130
The CEO & director of Dr. Eric M. Dube Ph.D.. is Travere Therapeutics Inc (TVTX), and CFO & Sr. VP is Dr. Eric M. Dube Ph.D..
There is no promoter pledging in Travere Therapeutics Inc (TVTX).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,012
|
|
|
990
|
|
|
974
|
|
|
896
|
| Travere Therapeutics Inc. (TVTX) | Ratios |
|---|---|
|
Return on equity(%)
|
-247.45
|
|
Operating margin(%)
|
-132.66
|
|
Net Margin(%)
|
-137.9
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Travere Therapeutics Inc (TVTX) was $0 Mln.
$0.35
(
